Sonoma Pharmaceuticals (SNOA) Cash from Investing Activities (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Cash from Investing Activities of -$47000.0 in Q4 2025, down 370.0% quarter-over-quarter from -$10000.0 in Q3 2025, and down 2250.0% on a YoY basis from $2186.0 in Q4 2024.
Sonoma Pharmaceuticals (SNOA) Cash from Investing Activities (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$47000.0 for Q4 2025.
- In Q4 2025, Cash from Investing Activities fell 2250.0% year-over-year to -$47000.0; the TTM figure through Dec 2025 stood at -$210000.0 (down 1300.0% YoY), while the FY2025 annual figure was -$80000.0, down 3900.0% from the prior year.
- Cash from Investing Activities was -$47000.0 for Q4 2025 at Sonoma Pharmaceuticals, down from -$10000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $34000.0 in Q4 2022 to a low of -$187000.0 in Q3 2022.
- Historically, Cash from Investing Activities has averaged -$31894.7 across 5 years, with a median of -$17000.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 121.95% in 2024, then tumbled 2250.0% in 2025.
- A 5-year view of Cash from Investing Activities shows it stood at $11000.0 in 2021, then soared by 209.09% to $34000.0 in 2022, then plunged by 102.94% to -$1000.0 in 2023, then slumped by 100.0% to -$2000.0 in 2024, then sank by 2250.0% to -$47000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$47000.0 (Q4 2025), -$10000.0 (Q3 2025), and -$106000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | 229.00 Mn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | -87.00 Mn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 743.70 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | -506.20 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | -60.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | -2.08 Bn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 25.99 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | -15.45 Mn |
| 10 | Sonoma Pharmaceuticals | 1.87 Mn | -693,829.94 | 1.65 Mn | -47,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -47,000.00 |
| Dec 31, 2025 | -47,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -106,000.00 |
| Jun 30, 2025 | -106,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Sep 30, 2024 | -26,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -5,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Mar 31, 2024 | 18,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -2,000.00 |
| Sep 30, 2023 | -2,000.00 |